Company Filing History:
Years Active: 2012
Title: Harsh Saigal: Innovator in Serotonin Research
Introduction
Harsh Saigal is an accomplished legal representative based in Fresno, California. He is recognized for his groundbreaking work in the field of serotonin research, with a particular focus on the 5-HT1A receptors. His innovative contributions have pushed the boundaries of our understanding and treatment of various neurological conditions.
Latest Patents
Harsh Saigal holds a patent titled "Compositions and methods related to serotonin 5-HT1A receptors." This patent describes contemplated substituted arylpiperazinyl compounds, most notably F-Mefway, which demonstrate desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. The compounds exhibit high binding affinity, optimal lipophilicity, and effective radiolabeling with fluorine in a single step. Notably, these compounds also show high target-to-non-target ratios in receptor-rich regions, making them valuable tools for quantitatively measuring 5-HT1A receptors and serotonin concentration changes in the living brain.
Career Highlights
Harsh's work at the University of California showcases his dedication to advancing scientific knowledge and innovation. His single patent reflects a deep understanding of receptor pharmacology and its applications in real-world scenarios. He continues to contribute to the research community through his inventive pursuits.
Collaborations
Harsh collaborates with esteemed colleagues, including Jogeshwar Mukherjee and Neil Saigal, to further enhance the impact of their collective research efforts. These collaborations have opened new avenues for exploration in serotonin receptor studies and have the potential to translate findings into therapeutic applications.
Conclusion
In summary, Harsh Saigal's contributions to the field of serotonin research mark him as a notable inventor in the realm of neuroscience. His innovative patent and collaborative work demonstrate the significance of research in developing effective therapeutic strategies. As he continues to explore the intricacies of serotonin receptors, his work holds promise for future advancements in mental health and neurological treatment.